We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

80 hedge funds and large institutions have $197M invested in Pacific Biosciences in 2013 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 27

7% more capital invested

Capital invested by funds: $184M → $197M (+$13.1M)

5% less call options, than puts

Call options by funds: $223K | Put options by funds: $234K

8% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 12

1% less funds holding

Funds holding: 81 → 80 (-1)

Holders
80
Holders Change
-1
Holders Change %
-1.23%
% of All Funds
2.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
36
Reduced
27
Closed
12
Calls
$223K
Puts
$234K
Net Calls
-$11K
Net Calls Change
-$313K

Top Buyers

Rank Fund Capital Flow
1
BIT
BlackRock Institutional Trust
California
+$8.36M
2
BA
BlackRock Advisors
Delaware
+$6.51M
3
MC
Maverick Capital
Texas
+$2.96M
4
OIM
Oracle Investment Management
Connecticut
+$2.82M
5
BIM
Bogle Investment Management
Massachusetts
+$2.59M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$8.71M
2
DM
Deerfield Management
New York
-$2.45M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.55M
4
EI
EAM Investors
California
-$1.12M
5
RFC
Russell Frank Company
Washington
-$967K
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
76
Creative Planning
Kansas
$6K +$4.59K +1,000 +1,000%
U
77
UBS
Switzerland
$4K – – –
Wells Fargo
78
Wells Fargo
California
$4K +$3.44K +750 New
BNP Paribas Financial Markets
79
BNP Paribas Financial Markets
France
$3.25K -$812K -176,770 -100%
TRCT
80
Tower Research Capital (TRC)
New York
$1K -$50.9K -11,087 -98%
Manulife (Manufacturers Life Insurance)
81
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$207 +$175K +38,142 +2,724%
RG
82
Redmile Group
California
– -$8.71M -1,574,379 Closed
Renaissance Technologies
83
Renaissance Technologies
New York
– -$1.55M -280,100 Closed
EI
84
EAM Investors
California
– -$1.12M -203,176 Closed
SIM
85
SSI Investment Management
California
– -$645K -116,710 Closed
CCM
86
Catapult Capital Management
New York
– -$276K -50,000 Closed
BRWA
87
B. Riley Wealth Advisors
Florida
– -$197K -35,626 Closed
Two Sigma Investments
88
Two Sigma Investments
New York
– -$165K -29,854 Closed
LMF
89
LMR Master Fund
Cayman Islands
– -$126K -22,809 Closed
VAM
90
Visium Asset Management
New York
– -$111K -20,000 Closed
BG
91
BlackRock Group
United Kingdom
– -$75K -13,520 Closed
Royal Bank of Canada
92
Royal Bank of Canada
Ontario, Canada
– -$11K -2,000 Closed
1 2 3
4

PACB Hedge Fund Activity: Q4 2013 in Review

80 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q4 2013, worth a combined $197M — up 7.2% from $184M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of PACB and 11 opened new positions — a net loss of 1 holder — while 27 trimmed existing stakes and 36 added.

The largest buyer was BlackRock Institutional Trust, adding an estimated $8.36M. The largest seller was Redmile Group, exiting entirely with an estimated $8.71M sold.

  • 80 institutional investors held Pacific Biosciences (PACB) as of Q4 2013, down from 81 in Q3 2013.
  • Funds reported $197M of Pacific Biosciences stock for Q4 2013, up 7.2% quarter-over-quarter.
  • 11 funds opened new Pacific Biosciences positions in Q4 2013 and 12 closed out, a net change of -1 holder.
  • The largest Pacific Biosciences buyer in Q4 2013 was BlackRock Institutional Trust, an estimated $8.36M added.
  • The largest Pacific Biosciences seller in Q4 2013 was Redmile Group, an estimated $8.71M sold.

Based on aggregated 13F filings for Q4 2013.